OBJECTIVE: To study the dynamics of pituitary prolactin secretion in RA, and its association with the HLA DR4 status in patients. METHODS: TRH stimulation of the pituitary secretion of PRL was performed in 23 RA patients and 8 control subjects, all of whom were post-menopausal women. Hormone concentrations were assessed by radioimmunoassay. RESULTS: Basal prolactin concentrations were higher in RA patients compared to controls (579 +/- 80 mu UI/ml versus 187 +/- 47, (p < 0.01). An increase in the prolactin response to TRH at 30 min (2257 +/- 218 mu UI/l versus 1074 +/- 207, p < 0.005), independent of disease activity, was observed in the RA patients. In DR4+ RA patients, we observed a higher PRL peak at 60 min. (3913 +/- 506 mu UI/ml versus 2120 +/- 443, p < 0.01), and an increased residual value at 120 min compared to DR4- RA patients. The area under the curve of the PRL response was also increased in DR4+ RA patients, suggesting higher PRL secretion compared to DR4- RA patients. CONCLUSION: In female, post-menopausal RA patients an alteration in pituitary prolactin release, not linked to disease activity, can be observed. In DR4+ RA patients, the overall prolactin secretion reflected by the AUC is increased compared to DR4- patients. These results suggest a dysregulation of the pituitary response in RA.
OBJECTIVE: To study the dynamics of pituitary prolactin secretion in RA, and its association with the HLA DR4 status in patients. METHODS: TRH stimulation of the pituitary secretion of PRL was performed in 23 RApatients and 8 control subjects, all of whom were post-menopausal women. Hormone concentrations were assessed by radioimmunoassay. RESULTS: Basal prolactin concentrations were higher in RApatients compared to controls (579 +/- 80 mu UI/ml versus 187 +/- 47, (p < 0.01). An increase in the prolactin response to TRH at 30 min (2257 +/- 218 mu UI/l versus 1074 +/- 207, p < 0.005), independent of disease activity, was observed in the RApatients. In DR4+ RApatients, we observed a higher PRL peak at 60 min. (3913 +/- 506 mu UI/ml versus 2120 +/- 443, p < 0.01), and an increased residual value at 120 min compared to DR4- RApatients. The area under the curve of the PRL response was also increased in DR4+ RApatients, suggesting higher PRL secretion compared to DR4- RApatients. CONCLUSION: In female, post-menopausal RApatients an alteration in pituitary prolactin release, not linked to disease activity, can be observed. In DR4+ RApatients, the overall prolactin secretion reflected by the AUC is increased compared to DR4- patients. These results suggest a dysregulation of the pituitary response in RA.
Authors: A M M Eijsbouts; F H J van den Hoogen; R F J M Laan; C G J Sweep; A R M M Hermus; L B A van de Putte Journal: Ann Rheum Dis Date: 2004-08-19 Impact factor: 19.103
Authors: Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera Journal: Cell Mol Life Sci Date: 2016-03-29 Impact factor: 9.261